F S&P 500
4,608.50 +1.00 (+0.02%) F Dow Jones
36,307.00 +27.00 (+0.07%) F Nasdaq
16,082.75 -15.50 (-0.10%) E-mini Russell 2000 Index Futur
1,885.30 +3.20 (+0.17%) Petróleo
71.44 +0.21 (+0.29%) Oro
2,022.10 +7.60 (+0.38%)
Altimmune, Inc. (ALT)
Fuera de horario:
Altimmune, Inc.
910 Clopper Road
Suite 201S
Gaithersburg, MD 20878
United States
240 654 1450
https://altimmune.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 52
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Vipin K. Garg Ph.D. | President, CEO & Director | 916.16k | N/D | 1958 |
| Mr. Richard I. Eisenstadt M.B.A. | Chief Financial Officer | 619.69k | N/D | 1958 |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer | 599.25k | N/D | 1959 |
| Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS | Chief Medical Officer | 643.04k | N/D | 1953 |
| Mr. Bertrand Georges Ph.D. | Chief Technology Officer | N/D | N/D | N/D |
| Mr. Tony Blandin B.S. | Vice President of Quality & Compliance Management | N/D | N/D | N/D |
| Mr. Raymond M. Jordt M.B.A. | Chief Business Officer | N/D | N/D | 1973 |
| Mr. Andrew Shutterly M.S. | Corporate Controller | N/D | N/D | N/D |
Descripción
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Gestión corporativa
La calificación ISS Governance QuickScore de Altimmune, Inc. a partir del 1 de diciembre de 2023 es 5. Las puntuaciones principales son Auditoría: 7; Junta: 3; Derechos del accionista: 4; Compensación: 8.
